Pluripotent stem cell applications for regenerative medicine

Current Opinion in Organ Transplantation

Volumn 20, Issue 6, 2015, Pages 663-670

  Angelos, Mathew G ^a   Kaufman, Dan S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cellular therapy; Clustered regulatory interspaced short palindromic repeats (CRISPR) Cas9; Gene therapy; Human clinical trials; Human pluripotent stem cells

Indexed keywords

CELL THERAPY; CLINICAL TRIAL (TOPIC); EMBRYONIC STEM CELL; GENE THERAPY; GENETIC DISORDER; HUMAN; MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; ANIMAL; HUMAN EMBRYONIC STEM CELL; INDUCED PLURIPOTENT STEM CELL; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HUMAN EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

EID: 84947126816     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000244     Document Type: Review

References (84)

1. Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-2394.
2. Ramsey BW, Davies J, McElvaney NG, et al. ACFTR potentiatorinpatients with cystic fibrosis and the G551D mutation. N Engl J Med 2010; 365:609-619.
3. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:877-889.
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemur-afenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
5. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-1147.
6. Bendall SC, Stewart MH, Menendez P, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007; 448:1015-1021.
7. Yao S, Chen S, Clark J, et al. Long-term self-renewal and directed differentiation of human embryonic stem cells in chemically defined conditions. Proc Natl Acad Sci USA 2006; 103:6907-6912.
8. Levenstein ME, Ludwig TE, Xu R-H, et al. Basic fibroblast growth factor support of human embryonic stem cell self-renewal. Stem Cells 2006; 24:568-574.
9. Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24:185-187.
10. Sato N, Meijer L, Skaltsounis L, et al. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10:55-63.
11. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells 2001; 19:193-204.
12. Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 2009; 114:3513-3523.
13. Kaufman DS, Thomson JA. Human ES cells: haematopoiesis and transplantation strategies. J Anat 2002; 200:243-248.
14. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-676.
15. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872.
16. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318:1917-1920.
17. Angelos MG, Kidwai F, Kaufman DS. Pluripotent stem cells and gene therapy. In: Laurence J, Franklin M, editors. Translating gene therapy to the clinic. Techniques and approaches Elsevier 2015; 12-26.
18. Rao MS, Malik N. Assessing iPSC reprogramming methods for their suitability in translational medicine. J Cell Biochem 2012; 113:3061-3068.
19. Park I-H, Arora N, Huo H, et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134:877-886.
20. Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321:1218-1221.
21. Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familialdysautonomiausingpatient-specificiPSCs.Nature2009;461:402-406.
22. Unternaehrer JJ, Daley GQ. Induced pluripotent stem cells for modelling human diseases. Philos Trans R Soc Lond B Biol Sci 2011; 366:2274-2285.
23. Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for Long-QT Syndrome. N Engl J Med 2009; 363:1397-1409.
24. Ebert AD, Yu J, Rose FF, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457:277-280.
25. Xu X, Lei Y, Luo J, et al. Prevention of b-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of cyclin-dependent kinases and associated cell cycle events. Stem Cell Res 2013; 10:213-227.
26. McNeish J, Roach M, Hambor J, et al. High-throughput screening inembryonic stem cell-derived neurons identifies potentiators of a-amino-3-hydroxyl-5-methyl-4-isoxazolepropionatetype glutamate receptors. J Biol Chem 2010; 285:17209-17217.
27. Egawa N, Kitaoka S, Tsukita K, et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012; 4:145ra104.
28. Ye L, Chang Y-H, Xiong Q, et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived car diovascular cells. Cell Stem Cell 2014; 15:750-761.
29. Pagliuca FW, Millman JR, Gürtler M, et al. Generation of functional human pancreatic b cells in vitro. Cell 2014; 159:428-439.
30. Li Y, Tsai Y-T, Hsu C-W, Erol D, et al. Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med 2012; 18 (9):1312-1319.
31. Cyranoski D. Stem cells cruise to clinic. Nature 2013; 494:413.
32. Cyranoski D. Japanese woman is first recipient of next-generation stem cells. Nature News 2014. doi:10.1038/nature.2014.15915.
33. Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005; 25:4694-4705.
34. Baker M. Stem-cell pioneer bows out. Nature 2011; 479: 459-1459.
35. Wirth E, Jones L, Priest C, et al. Update on a phase 1 safety trial of human embryonic stem cell-derived oligodendrocyte progenitor cells (GRNOPC1) in subjects with neurologically complete, subacute spinal cord injuries. In: Abstracts from the 2011 International Congress on Spinal Cord Medicine and Rehabilitation; 2011 Jun 4-8. p. 6.
36. Scott CT, Magnus D. Wrongful termination: lessons from the geron clinical trial. Stem Cells Transl Med 2014; 3:1398-1401.
37. Leach LL, Clegg DO. Concise review: making stem cells retinal: methods for deriving retinal pigment epithelium and implications for patients with ocular disease. Stem Cells 2015; 33:2363-2373.
38. Binder S, Stolba U, Krebs I, et al. Transplantation of autologous retinal pigment epithelium in eyes with foveal neovascularization resulting from age-related macular degeneration: a pilot study. Am J Ophthalmol 2002; 133:215-225.
39. Chen FK, Patel PJ, Uppal GS, et al. Long-term outcomes following full macular translocation surgery in neovascular age-related macular degeneration. Br J Ophthalmol 2010; 94:1337-1343.
40. Van Zeeburg EJT, Maaijwee KJM, Missotten TO, et al. A free retinal pigment epitheliumchoroid graft in patients with exudative age-related macular degeneration: Results up to 7 years. Am J Ophthalmol 2012; 153:120-127; e2.
41. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015; 385:509-516.
42. Takahashi M. Retinal cell therapy using iPS cells. Presentation In: International Society for Stem Cell Research Annual Meeting. Stockholm, Sweden. 2015 Jun 24-27. Meeting. 2015.
43. Menasché P, Vanneaux V, Fabreguettes J-R, et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur Heart J 2015; 36:743-750.
44. Bel A, Planat-Bernard V, Saito A, et al. Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. Circulation 2010; 122:S118-S123.
45. D'Amour KA, Bang AG, Eliazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 2006; 24:1392-1401.
46. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318:1920-1923.
47. Zou J, Maeder ML, Mali P, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009; 5:97-110.
48. Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009; 27:851-857.
49. Chang C-J, Bouhassira EE. Zinc-finger nuclease-mediated correction of a-thalassemia in iPS cells. Blood 2012; 120:3906-3914.
50. Brunet E, Simsek D, Tomishima M, et al. Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci USA 2009; 106:10620-10625.
51. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25:1298-1306.
52. Isalan M. Zinc-finger nucleases: how to play two good hands. Nat Methods 2011; 9:32-34.
53. DeFrancesco L. Move over ZFNs. Nat Biotechnol 2011; 29:681-684.
54. Ding Q, Lee YK, Schaefer EAK, et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12:238-251.
55. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29:731-734.
56. Osborn MJ, Starker CG, McElroy AN, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther 2013; 21:1151-1159.
57. Bergmann T. Progress and problems with viral vectors for delivery of talens. J Mol Genet Med 2014; 08:1-7.
58. Piganeau M, Ghezraoui H, De Cian A, et al. Cancer translocations in human cells induced by zinc finger and TALE nucleases. Genome Res 2013; 23:1182-1193.
59. Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. 2013; 8 (11):2281-2308.
60. Hsu PD, Scott DA, Weinstein JA, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013; 31:827-832.
61. Heigwer F, Kerr G, Boutros M. E-CRISP: fast CRISPR target site identification. Nat Methods 2014; 11:122-123.
62. Ding Q, Regan SN, Xia Y, et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 2013; 12:393-394.
63. Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/cas-mediated genome engineering. Cell 2013; 153:910-918.
64. Ran FA, Hsu PD, Lin CY, et al. Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing specificity. Cell 2013; 154:1380-1389.
65. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy ofhuman b-thalassaemia. Nature 2010; 467:318-322.
66. Xie F, Ye L, Chang JC, et al. Seamless gene correction of b-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014; 24:1526-1533.
67. Smith C, Abalde-Atristain L, He C, et al. Efficient and allele-specific genome editing of disease loci in human iPSCs. Mol Ther 2014; 23:570-577.
68. Flynn R, Grundmann A, Renz P, et al. CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. Exp Hematol 2015.
69. Li HL, Fujimoto N, Sasakawa N, et al. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 2014; 4:143-154.
70. Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474:212-215.
71. Schuetz C, Markmann JF. Immunogenicity of b-cells for autologous transplantation in type 1 diabetes. Pharmacol Res 2015; 98:60-68.
72. Simonson OE, Domogatskaya A, Volchkov P, Rodin S. The safety of human pluripotent stem cells in clinical treatment. Ann Med 2015; 1:1-11.
73. Li L, Baroja ML, Majumdar A, et al. Human embryonic stem cells posses immune-privileged properties. Stem Cells 2004; 22:448-456.
74. Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 2002; 99:9864-9869.
75. Swijnenburg RJ, Tanaka M, Vogel H, et al. Embryonic stem cell immunogeni-city increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005; 112 (9 SUPPL):166-173.
76. Swijnenburg R-J, Schrepfer S, Cao F, et al. In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev 2008; 17:1023-1029.
77. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (1):59-72.
78. Rao M, Ahrlund-Richter L, Kaufman DS. Concise review: cord blood banking, transplantation and induced pluripotent stem cell-success and opportunities. Stem Cells 2012; 30:55-60.
79. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol 2008; 26:739-740.
80. Carlsten M, Childs RW. Genetic manipulation of NK Cells for cancer immunotherapy: Techniques and clinical implications. Front Immunol 2015; 6:266.
81. Snanoudj R, De Préneuf H, Créput C, et al. Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 2006; 19:693-704.
82. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117:3921-3928.
83. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood. Blood 2011; 117:1061-1070.
84. Introna M, Rambaldi A. Mesenchymal stromal cells for prevention and treatment of graft-versus-host disease: successes and hurdles. Curr Opin Organ Transplant 2015; 20:72-78.